GlassScriptPhysician profile
Terrence X Dwyer
NPI 1962499103
$1,045.07
in general payments reported to CMS, 2019-2025
16 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $151 · 2023: $235 · 2024: $269 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $157.74 | 2021-2025 | Tremfya |
| Ucb, INC. | $134.10 | 2021-2023 | Cimzia |
| Glaxosmithkline, LLC. | $98.09 | 2024-2025 | Benlysta, Nucala |
| Amgen INC. | $96.66 | 2022-2024 | Enbrel, Otezla |
| Astrazeneca Pharmaceuticals LP | $91.44 | 2024-2025 | Saphnelo |
| Lilly USA, LLC | $91.29 | 2022-2024 | Taltz |
| Abbvie INC. | $76.17 | 2024 | |
| Aurinia Pharma U.S., INC. | $63.54 | 2022-2024 | Lupkynis |
| Vertos Medical, INC. | $59.44 | 2024 | Mild Device Kit |
| Mallinckrodt Hospital Products INC. | $39.34 | 2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $31.08 | 2025 | |
| Pfizer INC. | $27.77 | 2023 | |
| Horizon Therapeutics Plc | $27.47 | 2023 | Krystexxa |
| Kyowa Kirin, INC. | $20.16 | 2025 | |
| Ferring Pharmaceuticals INC. | $17.90 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Dwyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.